Establishment and Verification of a First-Order Derivative UV Spectrophotometric Technique for Quantifying Favipiravir in Bulk and Pharmaceutical Formulations

PDF

Published: 2023-11-06

Page: 600-607


Thippavati Jayasree

Department of Pharmaceutical Analysis, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

Madapathi Keerthana

Department of Pharmaceutical Analysis, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

Papagari Krishna Vamshi Reddy

Department of Pharmaceutical Analysis, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

Kappala Swetha

Department of Pharmaceutical Analysis, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

Jahnavi Bandla *

Department of Pharmaceutical Analysis, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

*Author to whom correspondence should be addressed.


Abstract

The primary aim of this study was to establish and validate a UV spectrophotometric method for quantifying Favipiravir in both bulk and pharmaceutical formulations using a first-order derivative technique. In this approach, acetonitrile was chosen as the solvent, and measurements were taken at a wavelength of 323 nm. The methodology was developed and subsequently validated in compliance with the ICH guidelines. The analysis revealed a strong linear response within a concentration range of 5-25 µg/ml, with a correlation coefficient of 0.9995. Furthermore, the method exhibited a low detection limit of approximately 0.48 µg/ml and a quantification limit of about 1.44 µg/ml. A comprehensive assessment of the method's precision, accuracy, specificity, and sensitivity produced consistently positive results. Given its robust and reliable performance, this technique can be effectively utilized for the routine analysis of Favipiravir in both bulk and pharmaceutical forms.

Keywords: Favipiravir, UV spectrophotometry, acetonitrile, method development, validation


How to Cite

Jayasree , T., Keerthana , M., Reddy , P. K. V., Swetha , K., & Bandla , J. (2023). Establishment and Verification of a First-Order Derivative UV Spectrophotometric Technique for Quantifying Favipiravir in Bulk and Pharmaceutical Formulations. Asian Journal of Advances in Research, 6(1), 600–607. Retrieved from https://jasianresearch.com/index.php/AJOAIR/article/view/256


References

Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life threatening RNA virus infections. Pharmacol Ther. 2020; 209:107512.

Du YX, Chen XP. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020;108(2):242-247.

Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic. J Virus Erad. 2020;6(2):45-51.

Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019; 32(2):176-86.

Pritee RA, Mirza SB. Analytical method development and validation of favipiravir in bulk and tablet formulation. Int J Pharm Pharm Res. 2022;26(1):52-64.

Ibrahim B. Comparison of HPLC and UV Spectrophotometric methods for quantification of favipiravir in pharmaceutical formulations. Iran J Pharm Res. 2021;20(3):57-65.

Sayyed NSA, Lajporiya M, Manjra M, Patel S, Aejaz A, Khan GJ. Analytical method development and validation and forced degradation stability indicating studies of favipiravir by RP-HPLC and UV in bulk and pharmaceutical dosage form. J Pharm Res Int. 2021;33(48B):254-71.

Santosh VG, Hanmant AB. Development and validation of UV-Spectrophotometric method for estimation of favipiravir. Int J Pharm Pharm Res. 2022;24(4):172- 9.

Jeevana Jyothi B, Venkata Kavya R. Ultraviolet spectrophotometric method development for estimation of new antiviral repurposing drug favipiravir. Asian J Pharm Clin Res. 2021;14(7):67-9.

Itigimatha N, Chadchan KS, Yallur BC, Hadagali MD. New Analytical Methods for the Determination of New Anti-Viral Drug Favipiravir: A Potential Therapeutic Drug Against Covid-19 Virus, in Bulk and Dosage Forms. Pharm Chem J. 2023; 56(10):1419-25.

Wrushali AP, Sonam BB, Jagdish VM, Ravindra LB, Tejaswini VT, Mitali NP, Aparna GV. Development of visible spectrophotometric methods for the analysis of favipiravir in pure drug and tablet formulation. GSC Biol Pharm Sci. 2022;20(02):184-95.

Nithila P, Raghavendrababu N, Padmavathi Y, Neena G, Sushma K, Poojitha A. New FTIR method development and validation for quantitative analysis of favipiravir in bulk and pharmaceutical dosage forms. Int J Curr Pharm Res. 2022;14(5):25-9.

Safa MM, Ahmed AH, Sherin FH, Amira HK. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc 2021;249:119241.

Ibraam EM, Heba E, Fathalla B, Adel EI. Green micellar solvent free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens. Microchem J. 2021;165:106189.

Pallavi VD, Kamalkishor GB. Bioanalytical method development and validation for the determination of favipiravir in spiked human plasma by using RP-HPLC. J Pharm Res Int. 2021;33(47A):275-81.

Duygu T. Development and validation of a rapid HPLC-DAD method for determination of favipiravir in pharmaceutical formulation. Clin Exp Health Sci. 2022;12:648-52.

Komarov TN, Karnakova PK, Archakova OA, Shchelgacheva DS, Bagaeva NS, Shohin IE, Zaslavskaya KY, Bely PA. Determination of favipiravir in human plasma by HPLC-UV. Drug Dev Regist. 2022;11(3):220–9.

Hailat M, Al-Ani I, Zakareia Z, Al-Shdefat R, Al-Meanazel O, Anwer MK, Hamad M, Abu Rayyan W, Awad R, Abu Dayyih W. Development and Validation of HPLC-DAD Method for the Determination of Favipiravir and Studying the Impact of Vitamin C on the Pharmacokinetics of COVID-19 Antiviral Drug Favipiravir. Separations 2022;9:303.

Hailat M, Al-Ani I, Hamad M, Zakareia Z, Abu Dayyih W. Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. Molecules. 2021; 26(13):3789.

Vishal Bansi Ghune and Amit Suryakant Tapkir. Method development and validation of favipiravir by RP-HPLC. Innov J Med Sci. 2022;6(2):13-19.

Bulduk I. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations. Acta Chromatogr. 2021;33:209-15.

Jyoti S, Pankaj Kumar S, Jaya S. Development and validation of RP-HPLC method for estimation of favipiravir API and its tablet dosage form using quality by design approach. J Pharm Negat Results. 2022;13(8):4115-26.

Nadendla R, Patchala A. A validated high performance liquid chromatographic method for the quantification of favipiravir by PDA detector. Int J Life Sci Pharma Res. 2021;11:181-8.

Kalshetti MS, Sagar GA. Development and validation of HPLC method for quantification of favipiravir in tablet. Res J Pharm Technol. 2022;15(3):1319-2.

L570 quantitative analysis of favipiravir spiked in plasma using by HPLC. Shimadzu Corporation. 2020.

Yamani NS, Annapurna MM. Stability indicating RP-HPLC method for the estimation of favipiravir in API and Pharmaceutical dosage forms (tablets). Res J Pharm Technol. 2022;15(12):5700.

Megahed SM, Habib AA, Hammad SF, Kamal AH. Chemometric approach based on factorial and Box-Behnken designs for determination of anti-coronavirus drug; favipiravir in bulk and spiked human plasma by green HPLC method. Turk J Anal Chem. 2021;3(2):70-8.

Jadhav A, Tandale P, Wasnik SK, Kolhe SD. Simple validation and estimation HPLC method for favipiravir. Int Res J Mod Eng Technol Sci. 2022;4(12):1100-6.

Sonu AV, Priyanka Y. Stability indicating HPLC method development and validation for estimation of favipiravir in pharmaceutical dosage form. World J Pharm Pharm Sci. 2021;10(5):1749- 60.

Patil AB, Mahaparale SP. Stability indicating RP-HPLC method development for estimation of favipiravir in bulk and pharmaceutical dosage form. World J Pharm Res. 2021;10(14):1444-65.

Abdallah IA, Hammad SF, Bedair A, Elshafeey AH, Mansour FR. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV. Bioanalysis. 2022; 14(4):205-16.

Abdallah IA, Hammad SF, Bedair A, Mansour FR. Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1189:123087.

Abdallah IA, Hammad SF, Bedair A, Abdelaziz MA, Danielson ND, Elshafeey AH, Mansour FR. A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid-liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. Biomed Chromatogr 2022;36(6):e5365.

Vemuri DK, Gundla R, Konduru N, Mallavarapu R, Katari NK. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method. Biomed Chromatogr 2022;36(6):e5363.

Jain B, Jain R, Jaiswal PK, Zughaibi T, Sharma T, Kabir A, Singh R, Sharma S. A Non-Instrumental Green Analytical Method Based on Surfactant-Assisted Dispersive Liquid-Liquid Microextraction-Thin-Layer Chromatography-Smartphone-Based Digital Image Colorimetry (SA-DLLME-TLC-SDIC) for Determining Favipiravir in Biological Samples. Molecules. 2023; 28(2):529.

Suleyman G, Aysen H, Ibrahim B. Development and validation of UPLC-MS/MS method for obtaining favipiravir tablet dosage form and evaluation of its behavior under forced conditions. J Pharm Res Int. 2021;33(56A):130-40.

Rezk MR, Badr KA, Abdel-Naby NS, Ayyad MM. A Novel, Rapid and Simple UPLC–MS/MS Method for Quantification of Favipiravir in Human Plasma: Application to a Bioequivalence Study. Biomed Chromatogr. 2021;35(7):e5098.

Eryavuz OD, Abusoglu S, Onmaz M, Yerlikaya FH, Unlu A. Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1176:122768.

Itigimath N, Ashoka H, Yallur BC, Hadagali MD. LC-MS/MS Method Development and Validation for the Determination of Favipiravir in Pure and Tablet Dosage Forms. Turk J Pharm Sci. 2022.

Morsy MI, Nouman EG, Abdallah YM, Zainelabdeen MA, Darwish MM, Hassan AY, Gouda AS, Rezk MR, Abdel-Megied AM, Marzouk HM. A Novel LC-MS/MS Method for Determination of the Potential Antiviral Candidate Favipiravir for the Emergency Treatment of SARS-CoV-2 Virus in Human Plasma; Application to a Bioequivalence Study in Egyptian Human Volunteers. J Pharm Biomed Anal. 2021;199:114057.

Dominic F, Lisa J, David M. LC-MS/MS analysis of small molecule anti-viral and anti-inflammatory drugs in plasma in clinical research. Waters Corporation; 2020.

Curley P, Neary M, Arshad U, Tatham L, Pertinez H, Box H, Rajoli RK, Valentijn A, Sharp J, Rannard SP, Owen A. Development of a highly sensitive bioanalytical assay for the quantification of favipiravir. Biorxiv. 2021.02.03;429628.

Erşan T, Dilgin DG, Kumrulu E, Kumrulu U, Dilgin Y. Voltammetric Determination of Favipiravir Used as an Antiviral Drug for the Treatment of Covid-19 at Pencil Graphite Electrode. Electroanalysis; 2022.

DOI: 10.1002/elan.202200295.

Mehmandoust M, Khoshnavaz Y, Tuzen M, Erk N. Voltammetric sensor based on bimetallic nanocomposite for determination of favipiravir as an antiviral drug. Mikrochim Acta. 2021;188(12):434.

Akca Z, Ozok HI, Yardim Y, Senturk Z. Electroanalytical investigation and voltammetric quantification of antiviral drug favipiravir in the pharmaceutical formulation and urine sample using a glassy carbon electrode in anionic surfactant media. Turk J Chem. 2022; 46(3):21

ICH Harmonized Triplicate Guideline. Validation of analytical procedures: Text and Methodology, Q2 (R1); 2005.